The Russian antidote has significant advantages in terms of efficiency, cost and logistics, scientists wrote on Twitter.
Some data collected from the second analysis of the third phase of clinical trials showed a 91,4% efficacy, based on 18,794 volunteers.
Some 100.000 Russians have been vaccinated so far, and the number is expected to exceed 2 million before the end of December.
The third phase of clinical trials is been also conducted in Belarus, Venezuela, the United Arab Emirates (UAE) and India.
Moscow used the emergency authorization to register its vaccines before fully completing the third phase of clinical trials; an approach that, according to its developers, other nations have been following including the United Kingdom (UK).
Unlike other proposals, Sputnik-V can be kept between two and eight degrees Celsius, and the total price of the two doses needed to vaccinate a person will be less than $20.
Over 50 countries have requested 1.2 billion doses and distribution in foreign markets will be carried out in collaboration with international partners of the Russian Fund for Direct Investment in Brazil, China, South Korea and India, among other countries.
mh/pll / mem / rbp
